Benzinga | Mar 1, 2021 07:57AM EST

Barclays Downgrades Beam Therapeutics to Equal-Weight, Raises Price Target to $90

Barclays analyst Gena Wang downgrades Beam Therapeutics (NASDAQ:BEAM) from Overweight to Equal-Weight and raises the price target from $47 to $90.